A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Mayo Clinic
Mayo Clinic
National Cancer Institute (NCI)
7 Hills Pharma, LLC
Immatics US, Inc.
Replimune Inc.
H. Lee Moffitt Cancer Center and Research Institute
H. Lee Moffitt Cancer Center and Research Institute
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Ohio State University Comprehensive Cancer Center
Neonc Technologies, Inc.
Institute of Oncology Ljubljana
Melanoma Institute Australia
UNICANCER
Melanoma Institute Australia
University of Utah
Massachusetts General Hospital
NYU Langone Health
Karolinska University Hospital
H. Lee Moffitt Cancer Center and Research Institute
Emory University
SWOG Cancer Research Network
Linnaeus Therapeutics, Inc.
Stanford University
Abramson Cancer Center at Penn Medicine
University Health Network, Toronto
Abramson Cancer Center at Penn Medicine
Iovance Biotherapeutics, Inc.
Fox Chase Cancer Center
Vastra Gotaland Region
University Hospital, Montpellier
The Netherlands Cancer Institute
Herlev Hospital
Sheba Medical Center